Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

| More on:
a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • This ASX cannabis share is on fire, rising by as much as 27% in early morning trading after the company released its March quarter results 
  • Althea reported a record quarter of cash receipts worth $9.24 million and a maiden monthly profit in the month of March
  • Althea CEO Josh Fegan described the month of March as "a landmark turning point" for the company                         

ASX cannabis share Althea Group Holdings Ltd (ASX: AGH) leapt by as much as 27% this morning after the company revealed record quarterly sales of $9.24 million.

The company also achieved its maiden monthly operating profit in March, and now expects its first quarter of profit in June.

Althea manufactures, sells, and distributes cannabis-based medicines and recreational products globally.

Shares in Althea are currently changing hands for 5.1 cents, 13.3% up on yesterday's close of 4.5 cents.

In earlier trading, they hit an intraday high of 5.7 cents, up 26.6%.

Let's look at the detail in the report.

Althea share price soars on 68% increase in sales

The company reported the following results for the three months to 31 March:

  • $9.24 million in cash receipts, up 68% on the prior corresponding period (pcp)
  • Net cash outflows of $1.63 million, down 24% pcp
  • Cash and cash equivalents of $5.3 million as of 31 March

What happened to this ASX cannabis share in March?

Althea has two business divisions — recreational cannabis and pharmaceutical cannabis.

The company reported a record $5.15 million in receipts for recreational cannabis during the March quarter, up 57% compared to the December 2022 quarter.

It also reported a record $3.75 million in receipts for medicinal cannabis, up 11% on December.

Althea recorded its maiden monthly operating profit in the month of March.

The ASX cannabis share is flying today on this news and may get a further boost if the company makes good on its expectations of a maiden quarterly profit in June.

Althea also said operating expenses fell during the March quarter as a result of cost-cutting programs.

In other news during the quarter, Althea announced it had secured a CAD$2 million loan facility from lenders in Canada.

In addition, the company announced a further $2.2 million of convertible debt funding. This was provided by an institutional investor in the United States.

The ASX cannabis share fell by 16.7% between 1 January and 31 March.

The S&P/ASX All Ordinaries Index (ASX: XAO) rose by 2.1% over the same time frame.

'A landmark turning point' says CEO

Althea CEO Joshua Fegan said:

March 2023 was a landmark turning point for the Company as we achieved record monthly cash receipts and a maiden monthly operating profit.

To close out the Quarter with such a strong month (March) sets us up well for an expected substantial improvement in cash flow position, and a quarterly operating profit, for the final quarter of FY23.

Motley Fool contributor Bronwyn Allen has positions in Althea Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Cannabis Shares

A man in a horse head mask and suit jumps for joy on a beach.
Cannabis Shares

Could ASX cannabis shares be set for a smoking hot rebound?

ASX cannabis stocks could be set for a strong finish to 2024.

Read more »

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »